RenovoRx Inc (RNXT): Next-Year EPS Estimate 46.67%
As of 2026-10-15, RenovoRx Inc (RNXT) has a next-year EPS growth estimate of 46.67%. Featured in 4 EPS revision reports, most recently on 2026-09-04.
On 2026-08-28, analyst consensus for RNXT's next-year EPS growth shifted from 41.12% to 46.67% — a positive change of 5.55 percentage points. The revised estimate has been sustained across 45 subsequent trading sessions. Current-year growth is projected at 17.97%.
What's Driving This
The primary driver is the analyst upgrade to next-year EPS growth, raised 5.55 percentage points to 46.67% on 2026-08-28. The closest
Generated 2026-10-02 from news as of 2026-10-02
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 46.67%
- EPS growth this year
- 17.97%
- EPS next quarter (est)
- -$0.06
- Last price
- $1.19
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-15 | 46.67% | 17.97% | -$0.06 | $1.19 |
| 2026-10-14 | 46.67% | 17.97% | -$0.06 | $1.12 |
| 2026-10-13 | 46.67% | 17.97% | -$0.06 | $1.15 |
| 2026-10-12 | 46.67% | 17.97% | -$0.06 | $1.25 |
| 2026-10-11 | 46.67% | 17.97% | -$0.06 | $1.28 |
| 2026-10-10 | 46.67% | 17.97% | -$0.06 | $1.28 |
| 2026-10-09 | 46.67% | 17.97% | -$0.06 | $1.28 |
| 2026-10-08 | 46.67% | 17.97% | -$0.06 | $1.33 |
| 2026-10-07 | 46.67% | 17.97% | -$0.06 | $1.37 |
| 2026-10-06 | 46.67% | 17.97% | -$0.06 | $1.39 |
| 2026-10-05 | 46.67% | 17.97% | -$0.06 | $1.47 |
| 2026-10-04 | 46.67% | 17.97% | -$0.06 | $1.58 |
| 2026-10-03 | 46.67% | 17.97% | -$0.06 | $1.58 |
| 2026-10-02 | 46.67% | 17.97% | -$0.06 | $1.58 |
| 2026-10-01 | 46.67% | 17.97% | -$0.06 | $1.55 |
| 2026-09-30 | 46.67% | 17.97% | -$0.06 | $1.56 |
| 2026-09-29 | 46.67% | 17.97% | -$0.06 | $1.57 |
| 2026-09-28 | 46.67% | 17.97% | -$0.06 | $1.55 |
| 2026-09-27 | 46.67% | 17.97% | -$0.06 | $1.66 |
| 2026-09-25 | 46.67% | 17.97% | -$0.06 | $1.66 |
| 2026-09-24 | 46.67% | 17.97% | -$0.06 | $1.68 |
| 2026-09-23 | 46.67% | 17.97% | -$0.06 | $1.63 |
| 2026-09-22 | 46.67% | 17.97% | -$0.06 | $1.70 |
| 2026-09-21 | 46.67% | 17.97% | -$0.06 | $1.67 |
| 2026-09-20 | 46.67% | 17.97% | -$0.06 | $1.69 |
| 2026-09-18 | 46.67% | 17.97% | -$0.06 | $1.69 |
| 2026-09-17 | 46.67% | 17.97% | -$0.06 | $1.73 |
| 2026-09-16 | 46.67% | 17.97% | -$0.06 | $1.55 |
| 2026-09-15 | 46.67% | 17.97% | -$0.06 | $1.72 |
| 2026-09-14 | 46.67% | 17.97% | -$0.06 | $1.69 |
Reports Featuring RNXT
Recent News
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa VasorumGlobeNewswire
- RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...GuruFocus.com
- RenovoRx Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 ResultGuruFocus.com
- RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of EnrollmentGlobeNewswire
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 197 days.
- Median return since detection
- -2.2%
- % of tickers in the green
- 45%
- Median return on winners
- +21.9%
- Large revisions captured
- 1879
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is RenovoRx Inc's next-year EPS growth estimate?▾
As of 2026-10-15, RenovoRx Inc (RNXT) has a next-year EPS growth estimate of 46.67%, based on analyst consensus.
When was the latest EPS estimate revision for RNXT?▾
The most recent revision occurred on 2026-08-28, when analysts adjusted the next-year EPS growth estimate from 41.12% to 46.67%.
What sector and industry does RenovoRx Inc belong to?▾
RenovoRx Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RNXT appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. RenovoRx Inc (RNXT) appears here because it was detected by our daily top-EPS-revision-performer screen.